AnaptysBio, Inc. ANAB Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $232.39M+108% | $234.6M+157% | $169.47M+196% | $123.16M+304% | $111.87M+387% | ||
| $128.78M-23.3% | $135.97M-17.0% | $153M-1.1% | $163.81M+14.2% | $167.98M+25.0% | ||
| $62.81M+42.2% | $50.74M+19.7% | $45.14M+6.3% | $45.5M+8.1% | $44.18M+1.6% | ||
| $191.59M-9.7% | $186.71M-9.5% | $198.14M-3.1% | $209.3M+8.5% | $212.16M+14.6% | ||
| $40.8M+141% | $47.9M+142% | -$28.68M+80.5% | -$86.14M+47.0% | -$100.29M+38.2% | ||
| 17.6%+107pp | 20.4%+146pp | -16.9%+241pp | -69.9%+463pp | -89.6%+617pp | ||
| -$67.43M-67.3% | -$60.96M-101% | -$55.88M— | -$46.38M— | -$40.29M— | ||
| —— | —— | -$84.55M+49.0% | -$132.52M+22.1% | -$140.58M+13.9% | ||
| $160K— | $164K— | —— | —— | —— | ||
| —— | —— | -$84.63M+48.9% | -$132.59M+22.1% | -$140.62M+13.9% | ||
| —— | —— | -$2.76+54.6% | -$4.42+30.4% | -$4.79+22.0% | ||
| $41.34M+141% | $48.46M+142% | -$28.1M+80.9% | -$85.56M+47.1% | -$99.7M+38.3% | ||
| 17.8%+107pp | 20.7%+146pp | -16.6%+240pp | -69.5%+461pp | -89.1%+614pp | ||
| $40.8M+141% | $47.9M+142% | -$28.68M+80.5% | -$86.14M+47.0% | -$100.29M+38.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is AnaptysBio, Inc.'s revenue?
- AnaptysBio, Inc. (ANAB) generated $232.4M in revenue over the trailing twelve months, up 107.7% year over year.
- Is AnaptysBio, Inc. profitable?
- AnaptysBio, Inc. is not currently profitable: it reported a net loss of $115.7M over the trailing twelve months, a -49.9% net margin.
- What is AnaptysBio, Inc.'s earnings per share?
- AnaptysBio, Inc.'s diluted EPS over the trailing twelve months is $-3.94.
- Where does AnaptysBio, Inc.'s income statement data come from?
- Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
